The SCAP-AD project seeks volunteers to validate new ultra-sensitive diagnostic methods for the early detection of Alzheimer's disease

The SCAP-AD project (Cognitive Screening and Personalized Approach for Alzheimer's and other Dementias), led by the CIEN Foundation and with the participation of the Barcelonaβeta Brain Research Center (BBRC), a research center of the Pasqual Maragall Foundation, seeks to apply precision medicine to improve the diagnosis and treatment of neurodegenerative diseases such as Alzheimer's.

A total of 13 centers from eight Autonomous Communities participate in the project, with the aim of validating precision medicine tools based on online cognitive assessment, genetic risk stratification and blood biomarkers for the identification of preclinical Alzheimer's disease. The BBRC coordinates the neuroimaging work of the participating centres, including the collection and archiving of the magnetic resonance images generated by each centre, their processing and quality control.

The study will create two large population cohorts. On the one hand, a digital cohort that will allow the use of an online cognitive assessment to be explored through a web platform aimed at the population over 60 years of age throughout the national territory. On the other hand, a large clinical validation cohort will be generated, also aimed at people over 60 years of age without a diagnosis of dementia, who will undergo a more in-depth study.

About SCAP-AD

The main goal of the project is to improve the diagnosis and prevention of Alzheimer's disease by integrating precision medicine tools that allow the creation of strategies to identify cases of the disease in very early stages.

The SCAP-AD project (PMP22/00022) is funded by the Carlos III Health Institute with funds from the European NextGenerationEU that finance the actions of the Recovery, Transformation and Resilience Plan.